Global trans-lesional computed tomography-derived fractional flow reserve gradient is associated with clinical outcomes in diabetic patients with non-obstructive coronary artery disease

Table 1 Baseline characteristics

Characteristic	No MACE (N = 1078)	MACE (N = 137)	P value
Age (year)	59.9 ± 10.2	61.4 ± 10.7	0.16
Male	570 (52.9%)	82 (59.9%)	0.12
Body mass index (kg/m²)	26.2 ± 3.6	26.3 ± 3.5	0.33
Cardiac risk factors
Hypertension	716 (66.4%)	94 (68.6%)	0.61
Hyperlipidemia	560 (51.9%)	94 (68.6%)	< 0.001
Current smoking	279 (25.9%)	48 (35.0%)	0.02
Family history of CAD	262 (24.3%)	33 (24.1%)	0.96
Framingham risk score	18 (16–20)	19 (17–21.5)	0.001
< 10%	8 (0.7%)	0 (0.0%)	0.31
10–20%	836 (77.6%)	90 (65.7%)	0.002
> 20%	234 (21.7%)	47 (34.3%)	0.001
Medication
Anti-platelet	408 (37.8%)	59 (43.1%)	0.24
Beta blocker	356 (33.0%)	45 (32.8%)	0.97
ACEI/ARB	243 (22.5%)	37 (27.0%)	0.24
Statin	395 (36.6%)	75 (54.7%)	< 0.001
Calcium channel blocker	222 (20.6%)	37 (27.0%)	0.08
Diabetic treatment
Diet only	219 (20.3%)	23 (16.8%)	0.33
Oral hypoglycemic agent^a	787 (73.0%)	98 (71.5%)	0.72
Insulin	253 (23.5%)	41 (29.9%)	0.10

Values are mean ± standard deviation, median (interquartile range) or n (%)
CAD coronary artery disease, MACE major adverse cardiovascular events
^aOral hypoglycemic agent included those from the biguanide, thiazolidinedione, sulfonylurea, meglitinide classes, α-glucosidase inhibitors, DPP-4 inhibitor and SGLT2 inhibitors

ISSN: 1475-2840